Loading...
Indian Pharmaceutical Exporter · Ayurvedic & Herbal Products Specialist · $12.2K Total Trade · DGFT Verified
Bharath Vaidyasala is an Indian pharmaceutical exporter with a total trade value of $12.2K across 2 products in 1 therapeutic categories. Based on 20 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bhasma ($8.8K), Ghrita ($3.4K), .
Bharath Vaidyasala, established in 1940 by P.O. Thomas Vaidyan in Punalur, Kollam district, Kerala, India, is a sole proprietorship specializing in Ayurvedic and herbal pharmaceutical formulations. The company operates under the legal entity identifier (LEI) 89450016HGP4EH1QIE75, registered with the Directorate General of Foreign Trade (DGFT) of the Ministry of Commerce and Industry, India. The firm's manufacturing facility is located at Jayabharatham building, Main Road, Punalur, Kollam district, 691305, India. As a sole proprietorship, Bharath Vaidyasala is owned and managed by an individual entrepreneur, with no publicly available information on the exact revenue or employee count. The company's official website is not specified in the available sources.
Bharath Vaidyasala operates across 1 therapeutic categories, with Ayurvedic & Herbal Products (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Ayurvedic & Herbal Products
2 products · 100.0% · $12.2K
Bharath Vaidyasala exports 2 pharmaceutical products across 1 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Bhasma | Ayurvedic & Herbal Products | $8.8K | 12 | 2.1% | 10 |
| 2 | Ghrita |
Headquarters, ownership, manufacturing facilities, and key leadership
Bharath Vaidyasala, established in 1940 by P.O. Thomas Vaidyan in Punalur, Kollam district, Kerala, India, is a sole proprietorship specializing in Ayurvedic and herbal pharmaceutical formulations. The company operates under the legal entity identifier (LEI) 89450016HGP4EH1QIE75, registered with the Directorate General of Foreign Trade (DGFT) of the Ministry of Commerce and Industry, India. The firm's manufacturing facility is located at Jayabharatham building, Main Road, Punalur, Kollam district, 691305, India. As a sole proprietorship, Bharath Vaidyasala is owned and managed by an individual entrepreneur, with no publicly available information on the exact revenue or employee count. The company's official website is not specified in the available sources.
Bharath Vaidyasala's manufacturing facility is situated in Punalur, Kollam district, Kerala, India. The plant specializes in the production of Ayurvedic and herbal pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the plant's capacity and certifications are not publicly disclosed. The facility operates under Good Manufacturing Practice (GMP) standards, ensuring the production of high-quality Ayurvedic products.
| $3.4K |
| 8 |
0.7% |
| 6 |
Bharath Vaidyasala exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $12.2K. The top category is Ayurvedic & Herbal Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Bharath Vaidyasala.
Request DemoSpecific information regarding the CEO, CFO, and other key executives of Bharath Vaidyasala is not publicly available. As a sole proprietorship, the company is likely managed by the owner, P.O. Thomas Vaidyan, who established the firm in 1940. However, detailed profiles of the leadership team are not provided in the available sources.
Regulated market presence, emerging market penetration, and geographic strategy
Bharath Vaidyasala has engaged in export activities to various international markets, including the United States, Bahrain, and Slovakia. The company has exported Ayurvedic products under HSN codes 30039011 and 30049011, indicating a focus on medicinal products. Specific regulatory filings, approvals, and market access statuses in these regions are not detailed in the available sources. The company's export data includes shipments to the United States, with records up to June 25, 2025. (en.nbd.ltd)
Bharath Vaidyasala has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to various countries, though specific details regarding WHO prequalification or other certifications enabling access to these markets are not provided in the available sources. The firm's focus on Ayurvedic products aligns with the growing global interest in traditional medicine, potentially facilitating market entry in these regions.
Bharath Vaidyasala's export activities demonstrate a strategic approach to market diversification, with shipments to the United States, Bahrain, and Slovakia. However, the company's portfolio concentration is high, with the top five products accounting for 100% of the export value. This indicates a reliance on a limited product range, which may pose risks if market dynamics change. The company's strategic direction appears to focus on leveraging its expertise in Ayurvedic formulations to cater to international markets, though further diversification in product offerings could enhance resilience.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding Bharath Vaidyasala's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data includes shipments to the United States, indicating some level of market access; however, detailed regulatory approvals and compliance statuses are not specified in the available sources.
There is no publicly available information confirming whether Bharath Vaidyasala holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The company's export data includes shipments to various international markets, suggesting adherence to certain international standards; however, specific certifications are not detailed in the available sources.
Bharath Vaidyasala operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds an Importer Exporter Code (IEC) issued by the Directorate General of Foreign Trade (DGFT), indicating compliance with Indian export regulations. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.
There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Bharath Vaidyasala. The company's export data does not indicate any recent regulatory actions or compliance issues. However, the absence of such information does not necessarily confirm a clean regulatory record.
Market share comparison, key differentiators, and strategic analysis
Bharath Vaidyasala operates in the Ayurvedic and herbal pharmaceutical sector, facing competition from both domestic and international manufacturers. While specific competitors are not identified in the available sources, the company's focus on Ayurvedic formulations positions it within a niche market segment. The firm's export data indicates a limited number of shipments, suggesting a smaller market share compared to larger competitors. The company's reliance on a narrow product range may also impact its competitive positioning.
Bharath Vaidyasala's key differentiators include its long-standing heritage in Ayurvedic medicine, with over 85 years of experience, and its commitment to producing authentic Ayurvedic and herbal products. The company's focus on traditional manufacturing methods, combined with modern quality standards, ensures the efficacy and safety of its products. However, the firm's high portfolio concentration and limited product diversification may pose challenges in adapting to changing market demands.
Bharath Vaidyasala's current strategic direction appears to focus on exporting Ayurvedic formulations to international markets, leveraging its expertise in traditional medicine. The company's export data indicates shipments to the United States, Bahrain, and Slovakia, suggesting a targeted approach to market expansion. Future outlooks would benefit from diversifying the product portfolio to reduce concentration risks and exploring additional international markets to enhance growth opportunities.
Track record assessment, certifications to verify, and pre-order checks
Bharath Vaidyasala's export data indicates a well-diversified sourcing network, with 40 shipments recorded from one verified supplier across the United States. The company's focus on Ayurvedic products aligns with the growing global interest in traditional medicine, potentially facilitating market entry in various regions. However, the firm's reliance on a limited number of suppliers and products may impact its ability to adapt to changing market dynamics.
Importers should verify the following certifications when considering products from Bharath Vaidyasala:
To verify these certifications, importers can request copies of the certificates directly from Bharath Vaidyasala or consult the respective certifying bodies' official websites for validation.
When conducting due diligence on Bharath Vaidyasala, importers should consider the following steps:
Red flags to watch for include expired or unverifiable certifications, inconsistent product quality, and a lack of transparency in business operations. Recommended pre-order checks involve conducting thorough background checks, reviewing contractual agreements, and ensuring clear communication regarding product specifications and delivery terms.
Bharath Vaidyasala exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Bhasma ($8.8K), Ghrita ($3.4K). Total export value is $12.2K.
Bharath Vaidyasala's total pharmaceutical export value is $12.2K, based on 20 verified shipments recorded in Indian Customs (DGFT) data.
Bharath Vaidyasala exports across 1 therapeutic categories. The largest are Ayurvedic & Herbal Products (100.0%, 2 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
1 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.